Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744375 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL647264 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL9744380 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL2712968 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| Hydrochloric Acid SCHEMBL30546580 | 0.98 | TSHR (0.36) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL5131640 | 0.98 | BTK (0.36) | TSHRBTKGAAKMT2A | |
| SCHEMBL4996407 | 0.98 | BTK (0.36) | TSHRBTKGAAKMT2A | |
| SCHEMBL3672475 | 0.97 | BTK (0.36) | TSHRBTKKMT2A | |
| SCHEMBL2350718 | 0.92 | KMT2A (0.34) | BTKGAAKMT2A | |
| SCHEMBL2350728 | 0.92 | KMT2A (0.34) | BTKGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12152017-B2 | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-11-26 | — | — | US | disclosed |
| CN-113015726-B | Ketone amide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-03-08 | — | — | CN | disclosed |
| CN-113197895-B | Pharmaceutical application of ketoamide compound | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4098258-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-20220112177-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | FUDAN UNIVERSITY (CN) | 2022-04-14 | — | — | US | disclosed |
| WO-2021151387-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
| CN-113197895-A | Pharmaceutical application of ketoamide compound | 中国科学院上海药物研究所 | 2021-08-03 | — | — | CN | disclosed |
| CN-113015726-A | Ketoamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-06-22 | — | — | CN | disclosed |
| US-5652258-A | HISTAMINE ANTAGONISTS | GLIATECH, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1996038141-A1 | 2-(1H-4(5)-IMIDAZOYL) CYCLOPROPYL DERIVATIVES | GLIATECH, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5270302-A | Derivatives of tetrapeptides as CCK agonists | ABBOTT LABORATORIES (US) | 1993-12-14 | — | — | US | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
| WO-1991019733-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0441191-A2 | Retroisosteric dipeptides, their preparation and use as renin inhibitors in pharmaceutical compositions | BAYER AG (DE) | 1991-08-14 | — | — | EP | disclosed |
| EP-0441192-A2 | Retroisosteric dipeptides, their preparation and use as renin inhibitors in pharmaceutical compositions | BAYER AG (DE) | 1991-08-14 | — | — | EP | disclosed |
| CN-1052685-A | Leather cleaning brightener for tourist shoes and its preparation method | UNIV BEIJING POLYTECHNIC (CN) | 1991-07-03 | — | — | CN | disclosed |
| EP-0376012-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112177-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | ACE, REN, ACE2 | TSHR 3993/4885BTK 3470/4885GAA 500/4885 |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | TSHR 3203/4885BTK 4362/4885GAA 91/4885 |
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | CTSV, CTSL, CTSS | TSHR 2450/4885BTK 3136/4885GAA 427/4885 |
| US-12152017-B2 | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | ACE, REN, ACE2 | TSHR 3993/4885BTK 3470/4885GAA 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.